- Medicine (St Vincent's) - Research Publications
Medicine (St Vincent's) - Research Publications
Permanent URI for this collection
76 results
Filters
Reset filtersSettings
Statistics
Citations
Search Results
Now showing
1 - 10 of 76
-
ItemOnce-Daily Roflumilast Foam 0.3% Improves Severity and Burden of Itch in Patients With Scalp and Body Psoriasis in a Randomized, Double-blind, Vehicle-Controlled Phase 2b StudyMoore, A ; Alonso-Llamazares, J ; Bhatia, N ; Devani, A ; Bukhalo, M ; Draelos, Z ; Gooderham, M ; Kempers, S ; Kircik, L ; Papp, K ; Pariser, D ; Sankeva, M ; Sinclair, R ; Zirwas, M ; Feng, A ; Burnett, P ; Higham, R ; Berk, D (National Society for Cutaneous Medicine, 2021-11-05)N/A
-
ItemTrichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management.Starace, M ; Iorizzo, M ; Sechi, A ; Alessandrini, AM ; Carpanese, M ; Bruni, F ; Vara, G ; Apalla, Z ; Asz-Sigall, D ; Barruscotti, S ; Camacho, F ; Doche, I ; Estrada, BD ; Dhurat, R ; Gavazzoni, MF ; Grimalt, R ; Harries, M ; Ioannidis, D ; McMichael, A ; Melo, DF ; Oliveira, R ; Ovcharenko, Y ; Pirmez, R ; Ramot, Y ; Rudnicka, L ; Shapiro, J ; Silyuk, T ; Sinclair, R ; Tosti, A ; Vano-Galvan, S ; Piraccini, BM (Elsevier BV, 2021-12)BACKGROUND: The cutaneous manifestations of COVID-19 may be useful disease markers and prognostic indicators. Recently, postinfectious telogen effluvium and trichodynia have also been reported. OBJECTIVE: To evaluate the presence of trichodynia and telogen effluvium in patients with COVID-19 and describe their characteristics in relation to the other signs and symptoms of the disease. METHODS: Patients with a history of COVID-19 presenting to the clinics of a group of hair experts because of telogen effluvium and/or scalp symptoms were questioned about their hair signs and symptoms in relation to the severity of COVID-19 and associated symptoms. RESULTS: Data from 128 patients were collected. Telogen effluvium was observed in 66.3% of the patients and trichodynia in 58.4%. Trichodynia was associated with telogen effluvium in 42.4% of the cases and anosmia and ageusia in 66.1% and 44.1% of the cases, respectively. In majority (62.5%) of the patients, the hair signs and symptoms started within the first month after COVID-19 diagnosis, and in 47.8% of the patients, these started after 12 weeks or more. LIMITATIONS: The recruitment of patients in specialized hair clinics, lack of a control group, and lack of recording of patient comorbidities. CONCLUSION: The severity of postviral telogen effluvium observed in patients with a history of COVID-19 infection may be influenced by COVID-19 severity. We identified early-onset (<4 weeks) and late-onset (>12 weeks) telogen effluvium.
-
ItemA review of actinic keratosis, skin field cancerisation and the efficacy of topical therapiesSinclair, R ; Baker, C ; Spelman, L ; Supranowicz, M ; MacMahon, B (WILEY, 2021-05)While a wide range of treatments exist for actinic keratosis and skin field cancerisation, the long-term benefits of the most common topical therapies are poorly defined. This report reviews the efficacy of the most commonly used topical therapies to treat regional or field lesions. Limited clinical and histopathological data are available on clearance rates at 12 months post-treatment for the most commonly used agents, with varied outcome measures making any comparison difficult. In general, total field clearance rates at 12 months are suboptimal for the most commonly employed agents. Given the increasing incidence of actinic keratosis and skin field cancerisation due to an ageing population, further research into the efficacy of therapies is critical to guide treatment choice.
-
ItemProxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial (Publication with Expression of Concern. See vol. 8, 2022) (Retracted article. See vol. 9, 2022)McCoy, J ; Goren, A ; Cadegiani, FA ; Vano-Galvan, S ; Kovacevic, M ; Situm, M ; Shapiro, J ; Sinclair, R ; Tosti, A ; Stanimirovic, A ; Fonseca, D ; Dorner, E ; Onety, DC ; Zimerman, RA ; Wambier, CG (FRONTIERS MEDIA SA, 2021-07-19)Antiandrogens have demonstrated a protective effect for COVOD-19 patients in observational and interventional studies. The goal of this study was to determine if proxalutamide, an androgen receptor antagonist, could be an effective treatment for men with COVID-19 in an outpatient setting. A randomized, double-blinded, placebo-controlled clinical trial was conducted at two outpatient centers (Brasilia, Brazil). Patients were recruited from October 21 to December 24, 2020 (clinicaltrials.gov number, NCT04446429). Male patients with confirmed COVID-19 but not requiring hospitalization (COVID-19 8-point ordinal scale <3) were administered proxalutamide 200 mg/day or placebo for up to 7 days. The primary endpoint was hospitalization rate at 30 days post-randomization. A total of 268 men were randomized in a 1:1 ratio. 134 patients receiving proxalutamide and 134 receiving placebo were included in the intention-to-treat analysis. The 30-day hospitalization rate was 2.2% in men taking proxalutamide compared to 26% in placebo, P < 0.001. The 30-day hospitalization risk ratio was 0.09; 95% confidence interval (CI) 0.03-0.27. Patients in the proxalutamide arm more frequently reported gastrointestinal adverse events, however, no patient discontinued treatment. In placebo group, 6 patients were lost during follow-up, and 2 patients died from acute respiratory distress syndrome. Here we demonstrate the hospitalization rate in proxalutamide treated men was reduced by 91% compared to usual care.
-
ItemSulfotransferase activity in plucked hair follicles predicts response to topical minoxidil treatment in Brazilian female pattern hair loss patientsRamos, PM ; Sinclair, R ; Miot, HA ; Goren, A (WILEY, 2020-01)
-
ItemAlopecia universalis treated with simvastatin/ezetimibe, minoxidil, and prednisolone in a 6-year-old girlIsmail, FF ; Sinclair, R (WILEY, 2020-04)
-
ItemTildrakizumab for treatment of refractory pyoderma gangrenosum of the penis and polymyalgia rheumatica: Killing two birds with one stoneJohn, JM ; Sinclair, RD (WILEY, 2020-05)
-
ItemClinical healing of erosive oral lichen planus with tildrakizumab implicates the interleukin-23/interleukin-17 pathway in the pathogenesis of lichen planusIsmail, FF ; Sinclair, R (WILEY, 2020-05)
-
ItemSuccessful treatment of refractory folliculitis decalvans with secukinumabIsmail, FF ; Sinclair, R (WILEY, 2020-05)
-
ItemOral minoxidil bio-activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern hair lossRamos, PM ; Goren, A ; Sinclair, R ; Miot, HA (WILEY, 2020-01)